CA2643732C - Composes oxysterols et voie - Google Patents

Composes oxysterols et voie Download PDF

Info

Publication number
CA2643732C
CA2643732C CA2643732A CA2643732A CA2643732C CA 2643732 C CA2643732 C CA 2643732C CA 2643732 A CA2643732 A CA 2643732A CA 2643732 A CA2643732 A CA 2643732A CA 2643732 C CA2643732 C CA 2643732C
Authority
CA
Canada
Prior art keywords
oxy
oxysterols
cells
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2643732A
Other languages
English (en)
Other versions
CA2643732A1 (fr
Inventor
Farhad Parhami
Michael E. Jung
Jennifer R. Dwyer
Khanhlinh Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of CA2643732A1 publication Critical patent/CA2643732A1/fr
Application granted granted Critical
Publication of CA2643732C publication Critical patent/CA2643732C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Surgical Instruments (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne notamment des oxystérols synthétiques. L'invention se rapporte aussi à des procédés d'utilisation desdits composés, notamment pour traiter des sujets ayant besoin d'un tel traitement, ainsi qu'à des compositions pharmaceutiques et à des kits permettant de mettre en oeuvre lesdits procédés.
CA2643732A 2006-02-27 2007-02-27 Composes oxysterols et voie Active CA2643732C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77699006P 2006-02-27 2006-02-27
US60/776,990 2006-02-27
US80273706P 2006-05-22 2006-05-22
US60/802,737 2006-05-22
US80973606P 2006-05-31 2006-05-31
US60/809,736 2006-05-31
PCT/US2007/005073 WO2007098281A2 (fr) 2006-02-27 2007-02-27 Composés oxystérols et voie

Publications (2)

Publication Number Publication Date
CA2643732A1 CA2643732A1 (fr) 2007-08-30
CA2643732C true CA2643732C (fr) 2012-08-21

Family

ID=38438024

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2643732A Active CA2643732C (fr) 2006-02-27 2007-02-27 Composes oxysterols et voie

Country Status (6)

Country Link
US (1) US9670244B2 (fr)
EP (1) EP1993558B1 (fr)
JP (1) JP2009528291A (fr)
AU (1) AU2007217366A1 (fr)
CA (1) CA2643732C (fr)
WO (1) WO2007098281A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503819A (ja) 2002-08-29 2006-02-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨形成を増進するための作用剤および方法
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
JP2009512422A (ja) * 2005-09-02 2009-03-26 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 骨形成及び抗脂肪細胞形成オキシステロール類
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2008036239A2 (fr) * 2006-09-19 2008-03-27 Wyeth Utilisation d'agonistes lxr pour le traitement de l'ostéoarthrite
CA2673513A1 (fr) 2006-12-19 2008-07-10 The Regents Of University Of California Inhibition de l'expression de ppar gamma par des oxysterols osteogenes specifiques
US20100112030A1 (en) * 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CN101951915A (zh) * 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
US20120309730A1 (en) * 2010-02-16 2012-12-06 The Johns Hopkins University Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
CN113956315A (zh) 2011-09-08 2022-01-21 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
EP2847205A4 (fr) * 2012-05-07 2016-01-20 Univ California Nouvel analogue de l'oxystérol, l'oxy149, pour l'ostéo-induction, la signalisation hedgehog et l'inhibition de l'adipogenèse
EP2847206A4 (fr) 2012-05-07 2016-01-20 Univ California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
EP2970504A4 (fr) * 2013-03-13 2017-01-18 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
ES2886506T3 (es) 2013-03-13 2021-12-20 Sage Therapeutics Inc Esteroides neuroactivos
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
CA2945404A1 (fr) * 2014-05-02 2015-11-05 The Regents Of The University Of California Analogues de bisphosphonates d'oxysterol osteogeniques ciblant specifiquement l'os
CN104327147B (zh) * 2014-06-04 2016-11-23 正源堂（天津滨海新区）生物科技有限公司 一种麦角甾醇类化合物及其制备方法与应用
EP4306114A1 (fr) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
CN107427526B (zh) 2014-12-09 2021-08-03 华沙整形外科股份有限公司 涉及甾醇的化合物和方法
US9878070B2 (en) 2015-06-17 2018-01-30 Warsaw Orthopedic, Inc. Malleable implants including an oxysterol and methods of use
US9987289B2 (en) 2015-07-10 2018-06-05 Warsaw Orthopedic, Inc. Slow release oxysterols and methods of use
US10632230B2 (en) 2015-07-10 2020-04-28 Warsaw Orthopedic, Inc. Implants having a high drug load of an oxysterol and methods of use
CA2986753A1 (fr) * 2015-06-17 2016-12-22 Warsaw Orthopedic, Inc. Implants comprenant un oxysterol et procedes d'utilisation
US9877836B2 (en) 2015-07-10 2018-01-30 Warsaw Orthopedic, Inc. Compression resistant implants including an oxysterol and methods of use
MA54851A (fr) 2015-07-06 2021-12-08 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CA2991311A1 (fr) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols et leurs procedes d'utilisation
HUE053778T2 (hu) 2015-07-06 2021-07-28 Sage Therapeutics Inc Oxiszterinek és ezek alkalmazása
WO2017074957A1 (fr) * 2015-10-26 2017-05-04 MAX BioPharma, Inc. Oxystérols et signalisation hedgehog
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3481846B1 (fr) 2016-07-07 2021-05-12 Sage Therapeutics, Inc. Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
BR112019006365A2 (pt) 2016-09-30 2019-08-06 Sage Therapeutics Inc oxisteróis substituídos c7 e métodos de utilização dos mesmos
JP2019532079A (ja) 2016-10-18 2019-11-07 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
EP3529257B1 (fr) 2016-10-18 2023-05-10 Sage Therapeutics, Inc. Oxystérols et leurs procédés d'utilisation
US11384114B2 (en) 2016-12-09 2022-07-12 Warsaw Orthopedic, Inc. Polymorphic forms of an oxysterol and methods of making them
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
US11690834B2 (en) * 2017-06-23 2023-07-04 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Composition, uses, and methods of treating spinal disc degeneration through sonic hedgehog signaling pathway
KR102060722B1 (ko) * 2017-11-06 2020-02-11 연세대학교 산학협력단 스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법
CN115010781B (zh) * 2022-07-15 2022-10-25 中节能万润股份有限公司 一种高纯度胆固醇的制备方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB869007A (en) 1956-10-03 1961-05-25 Ciba Ltd New heterocyclically substituted steroids
CH433275A (de) 1963-07-09 1967-04-15 Hoffmann La Roche Verfahren zur Herstellung von 19-Alkylsteroiden
JPS5111114B1 (fr) 1969-03-14 1976-04-08
US3887545A (en) 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4264512A (en) * 1975-09-29 1981-04-28 The Regents Of The University Of California 3-Deoxy-1α-hydroxy- and 3-deoxy-1α,25-dihydroxycholecalciferol and processes for the preparation thereof
US4183852A (en) 1977-07-18 1980-01-15 Kaiser Emil T Process for preparing 25-hydroxycholesterol
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
EP0487587A1 (fr) 1989-08-18 1992-06-03 Chiron Corporation Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
GB9118465D0 (en) 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
EP0650370A4 (fr) 1992-06-08 1995-11-22 Univ California Procedes et compositions permettant de cibler des tissus specifiques.
EP0644946A4 (fr) 1992-06-10 1997-03-12 Us Health Particules vecteurs resistantes a l'inactivation par le serum humain.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK0733103T3 (da) 1993-11-09 2004-07-12 Univ Johns Hopkins Fremstilling af höje titre af rekombinante AAV vektorer
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
EP0738275B9 (fr) 1994-01-06 2001-03-21 Sri International Composes antiandrogenes, preparations pharmaceutiques associees et leurs modes d'utilisation
EP0954317B1 (fr) 1996-04-09 2007-06-06 The University Of Edinburgh Utilisation de steroides a substitution 7 alpha pour traiter les troubles neuropsychiatriques
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6893830B1 (en) 1996-09-27 2005-05-17 The Board Of Regents Of The University Of Texas System Method of screening oxysterol activation of LXRα
US5840752A (en) 1996-11-21 1998-11-24 Henry; James P. Reduction of hair growth
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6080779A (en) 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
AU5928898A (en) 1997-01-24 1998-08-18 Regents Of The University Of California, The Use of fxr, pparalpha and lxralpha activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
KR20010012643A (ko) 1997-05-16 2001-02-26 에프.지.엠. 헤르만스 20-아랄킬-5α-프레그난 유도체
DE19723794A1 (de) 1997-06-06 1998-12-10 Jenapharm Gmbh Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität
US5929062A (en) 1997-06-19 1999-07-27 University Of Western Ontario Oxysterol inhibition of dietary cholesterol uptake
WO1999000117A2 (fr) 1997-06-27 1999-01-07 Ontogeny, Inc. Procedes et reactifs neuroprotecteurs
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999045923A1 (fr) 1998-03-13 1999-09-16 Merck & Co., Inc. Methodes visant a bloquer la resorption osseuse
EP0943332A1 (fr) 1998-03-19 1999-09-22 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Prophylaxie et traitement des adhésions
US6906069B1 (en) 1999-01-08 2005-06-14 Amgen Inc. LXR modulators
AU3285000A (en) 1999-03-09 2000-09-28 Akzo Nobel N.V. 22r-hydroxycholesta-8,14-diene derivatives for the inhibition of meiosis
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
AU1291901A (en) 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
GB0101933D0 (en) 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
KR101027485B1 (ko) 2001-02-12 2011-04-06 에이에스엠 아메리카, 인코포레이티드 반도체 박막 증착을 위한 개선된 공정
EP1401469A2 (fr) 2001-04-09 2004-03-31 Lorantis Limited Hedgehog
AU2003218180B2 (en) 2002-03-15 2008-03-20 Georgetown University Neuroprotective spirostenol pharmaceutical compositions
JP2006503819A (ja) 2002-08-29 2006-02-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨形成を増進するための作用剤および方法
DE10307104A1 (de) 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
WO2005028616A2 (fr) 2003-07-24 2005-03-31 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions morphogenes et leurs methodes d'utilisation pour le traitement de maladies cardiaques
EP1697413A2 (fr) 2003-08-18 2006-09-06 Wyeth Nouveaux variants lxr alpha humains
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
JP2007517801A (ja) 2003-12-24 2007-07-05 ユニバーシティー オブ ルイヴィル リサーチ ファウンデーション 骨との相互作用のために骨に作用物質を運ぶための骨標的化合物
US20080015173A1 (en) 2004-06-10 2008-01-17 Blizzard Timothy A Estrogen Receptor Modulators
EP1781779A2 (fr) 2004-08-02 2007-05-09 Novozymes A/S Création de diversité dans des polypeptides
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
WO2006034356A2 (fr) 2004-09-20 2006-03-30 The Board Of Trustees Of The Leland Stanford Junior University Genes associes a la surcharge de pression cardiaque
WO2006048264A2 (fr) 2004-11-04 2006-05-11 Roche Diagnostics Gmbh Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
US20090202660A1 (en) 2005-04-07 2009-08-13 The Regents Of The University Of California Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation
CA2608359A1 (fr) 2005-05-13 2006-11-23 Duke University Signatures d'expression genetique pour la deregulation de mecanismes oncogeniques
JP2009512422A (ja) 2005-09-02 2009-03-26 ザ リージェンツ オブ ザ ユニヴァーシティー オブ カリフォルニア 骨形成及び抗脂肪細胞形成オキシステロール類
US9670244B2 (en) 2006-02-27 2017-06-06 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
WO2007106507A2 (fr) 2006-03-14 2007-09-20 Petrie Howard T Détection de l'expression génique dans un échantillon ou un tissu mixte
WO2007130423A2 (fr) 2006-05-01 2007-11-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Marqueurs biologiques de tissu de plaie chronique et méthodes d'utilisation pour des critères de débridement chirurgical
US20100048944A1 (en) 2006-07-19 2010-02-25 Farhad Parhami Interactions of hedgehog and liver x receptor signaling pathways
US20080070883A1 (en) 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
GB0619860D0 (en) 2006-10-06 2006-11-15 Birkeland Innovasjon As Treatment of insulin resistance and disorders associated therewith
CA2673513A1 (fr) 2006-12-19 2008-07-10 The Regents Of University Of California Inhibition de l'expression de ppar gamma par des oxysterols osteogenes specifiques
US8071575B2 (en) 2007-02-23 2011-12-06 University Of Louisville Research Foundation Methods and compounds for the targeted delivery of agents to bone for interaction therewith
WO2008109780A1 (fr) 2007-03-06 2008-09-12 University Of Louisville Research Foundation, Inc Procédés et composés pour l'administration ciblée d'agents à un os pour une interaction avec celui-ci
US20100112030A1 (en) 2007-03-16 2010-05-06 The Regents Of The University Of California Role of hedgehog signaling in atherosclerosis and cardiovascular disease
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
MY163799A (en) 2008-02-07 2017-10-24 Dsg Tech Holdings Limited Method of making an absorbent composite and absorbent articles employing the same
WO2011006087A1 (fr) 2009-07-10 2011-01-13 The Regents Of The University Of California Inhibition de l'expression des ppar gamma dans les cellules préadipocytaires au moyen d'oxystérols
US20120309730A1 (en) 2010-02-16 2012-12-06 The Johns Hopkins University Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2012024581A2 (fr) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Composés oxystérol
WO2012024583A2 (fr) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Composés oxystérol
WO2012024584A2 (fr) 2010-08-20 2012-02-23 Fate Therapeutics, Inc. Composés oxystérol
EP2847206A4 (fr) 2012-05-07 2016-01-20 Univ California Oxy133, un analogue de l'oxystérol, induisant l'ostéo-genèse et la signalisation hedgehog et inhibant l'adipogenèse
EP2847205A4 (fr) 2012-05-07 2016-01-20 Univ California Nouvel analogue de l'oxystérol, l'oxy149, pour l'ostéo-induction, la signalisation hedgehog et l'inhibition de l'adipogenèse
CN105263500A (zh) 2013-05-02 2016-01-20 加利福尼亚大学董事会 骨选择性成骨性氧固醇-骨靶向剂
CA2945404A1 (fr) 2014-05-02 2015-11-05 The Regents Of The University Of California Analogues de bisphosphonates d'oxysterol osteogeniques ciblant specifiquement l'os

Also Published As

Publication number Publication date
EP1993558B1 (fr) 2014-07-30
US20100034781A1 (en) 2010-02-11
CA2643732A1 (fr) 2007-08-30
EP1993558A2 (fr) 2008-11-26
JP2009528291A (ja) 2009-08-06
WO2007098281A3 (fr) 2008-01-03
EP1993558A4 (fr) 2010-08-18
WO2007098281A2 (fr) 2007-08-30
US9670244B2 (en) 2017-06-06
AU2007217366A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CA2643732C (fr) Composes oxysterols et voie
US8022052B2 (en) Inhibition of PPAR gamma expression by specific osteogenic oxysterols
Chow et al. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol
CA2707663C (fr) Oxysterols pour l'activation du signal hedgehog, de l'osteoinduction, de l'anti-adipogenese et du signal wnt
Duez et al. Regulation of bile acid synthesis by the nuclear receptor Rev-erbα
Johnson et al. Novel oxysterols have pro‐osteogenic and anti‐adipogenic effects in vitro and induce spinal fusion in vivo
CN108191940B (zh) 合成胆汁酸组合物、方法和制剂
WO2011006087A1 (fr) Inhibition de l'expression des ppar gamma dans les cellules préadipocytaires au moyen d'oxystérols
KR20150008160A (ko) 골형성 및 헤지호그 신호전달을 유도하고 지방생성을 억제하는 신규 옥시스테롤 유사체 oxy149
Donna et al. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease
Stappenbeck et al. Novel oxysterols activate the Hedgehog pathway and induce osteogenesis
Maurya et al. Synthesis and biological evaluation of heterocyclic analogues of pregnenolone as novel anti-osteoporotic agents
Hamel et al. Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells
Li et al. HIF1α Promotes BMP9‐Mediated Osteoblastic Differentiation and Vascularization by Interacting with CBFA1
US6900191B1 (en) 1α-Hydroxyvitamin D5, its synthesis and use in cancer prevention
Zeng et al. Optimization and Impurity Control Strategy for Lithocholic Acid Production Using Commercially Plant-Sourced Bisnoralcohol
Murakami et al. Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700
Schönecker et al. Synthesis and biological activities of 2α-chloro-1-epicalcitriol and 1-epicalcitriol
Agellon Bile acids: At the crossroads of sterol, fat and carbohydrate metabolism
Khanka et al. Nature-Mimicking 3-Aryl-2h-Chromene Derivatives as Potential Bone Anabolic Agents
Wetzel Development of potent and selective inhibitors of 17β-hydroxysteroid dehydrogenase type 2: a new target for the treatment of osteoporosis
Keifari Estrogen like agents as anticancer drugs: Theory, synthesis and analysis

Legal Events

Date Code Title Description
EEER Examination request